Global Cancer Targeted Therapy Market By Type (Tumor Antigens As Targets of Antibodies, Development of Antibodies for Clinical Purposes, Complement Dependent Cytotoxicity (CDC), and Signal Transduction Changes), By Application (Hospital, and Clinic), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019-2028
- Published date: Aug 2022
- Report ID: 41426
- Number of Pages: 310
- Format:
- keyboard_arrow_up
- 1. Cancer Targeted Therapy Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Cancer Targeted Therapy Market Overview
- 3.1. Cancer Targeted Therapy Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Production Analysis by Region/Company
- 3.9. Industry chain Analysis
- 3.10. Marketing Strategy
- 3.1. Cancer Targeted Therapy Market Dynamics
- 4. Global Cancer Targeted Therapy Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Cancer Targeted Therapy Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. Tumor Antigens As Targets of Antibodies
- 4.4. Development of Antibodies for Clinical Purposes
- 4.5. Complement Dependent Cytotoxicity (CDC)
- 4.6. Signal Transduction Changes
- 5. Global Cancer Targeted Therapy Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Cancer Targeted Therapy Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. Hospital
- 5.4. Clinic
- 6. Global Cancer Targeted Therapy Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.2.1. Europe
- 6.2.1. Europe Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Spain
- 6.2.1.7. Rest of Europe
- 6.2.1. Europe Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia-Pacific
- 6.3.1. Asia-Pacific Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Cancer Targeted Therapy Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Cancer Targeted Therapy Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. Advaxis
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. Bind Therapeutics
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. Boehringer Ingelheim
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. Bristol Mayer Squibb
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. Celldex Therapeutics
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. Dendreon Corporation
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Eli Lily
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. GalaxoSmithKline
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. Galena Biopharma
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. Genetech
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 7.13. ImmunoCellular Therapeutics
- 7.13.1. Company Overview
- 7.13.2. Financial Highlights
- 7.13.3. Product Portfolio
- 7.13.4. SWOT Analysis
- 7.13.5. Key Strategies and Developments
- 7.14. ImmunoGen
- 7.14.1. Company Overview
- 7.14.2. Financial Highlights
- 7.14.3. Product Portfolio
- 7.14.4. SWOT Analysis
- 7.14.5. Key Strategies and Developments
- 7.15. Inovio Pharmaceuticals
- 7.15.1. Company Overview
- 7.15.2. Financial Highlights
- 7.15.3. Product Portfolio
- 7.15.4. SWOT Analysis
- 7.15.5. Key Strategies and Developments
- 7.16. Johnson & Johnson
- 7.16.1. Company Overview
- 7.16.2. Financial Highlights
- 7.16.3. Product Portfolio
- 7.16.4. SWOT Analysis
- 7.16.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- 1. Cancer Targeted Therapy Market Introduction
- Advaxis
- Bind Therapeutics
- Boehringer Ingelheim
- Bristol Mayer Squibb
- Celldex Therapeutics
- Dendreon Corporation
- Eli Lily
- GalaxoSmithKline
- Galena Biopharma
- Genetech
- ImmunoCellular Therapeutics
- ImmunoGen
- Inovio Pharmaceuticals
- Johnson & Johnson
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |